Protocol-based CT-guided brachytherapy for patients with prostate cancer and previous rectal extirpation-a curative approach.
CT-guided brachytherapy
Curative brachytherapy protocol
High-dose rate brachytherapy prostate
Image-guided brachytherapy
Prostate cancer brachytherapy
Prostate cancer treatment
Radiation therapy prostate cancer
Rectal extirpation
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
14
04
2024
accepted:
28
06
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
aheadofprint
Résumé
There are numerous curative treatment possibilities for prostate cancer. In patients who have undergone rectal extirpation for rectal cancer treatment, curative options are limited due to anatomic changes and previous irradiation of the pelvis. In this analysis, we validate the feasibility of CT-guided transperineal interstitial brachytherapy for this specific scenario. We analyzed the treatment procedures and outcomes of 5 patients with metachronic nonmetastatic prostate cancer. Ultrasound-guided brachytherapy was not possible in any of the patients. Of these 5 patients, 3 were treated for prostate cancer using temporary brachytherapy with Ir-192 only, and 2 were treated with external-beam radiation therapy and temporary brachytherapy as a boost. CT-guided brachytherapy was performed in all patients. We analyzed the feasibility, efficacy, treatment-related toxicity, and quality of life (EORTC-30, IEFF, IPSS, and ICIQ questionnaires) of the treatments. Median follow-up was 35 months. Two out of five patients received boost irradiation (HDR 2 × 9 Gy, PDR 30 Gy). Three out of five patients were treated with PDR brachytherapy in two sessions up to a total dose of 60 Gy. Dosimetric parameters were documented as median values as follows: V100 94.7% (94.5-98.4%), D2 CT-guided transperineal brachytherapy of the prostate in patients with previous rectal surgery and radiation therapy is safe and represents a possible curative treatment option. Brachytherapy can be considered for patients with metachronic prostate cancer in this specific scenario, albeit preferably in experienced high-volume centers.
Identifiants
pubmed: 39095649
doi: 10.1007/s00066-024-02266-y
pii: 10.1007/s00066-024-02266-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Wang TH, Liu CJ, Chao TF, Chen TJ, Hu YW (2018) Second primary malignancy risk after radiotherapy in rectal cancer survivors. World J Gastroenterol 24(40):4586–4595
doi: 10.3748/wjg.v24.i40.4586
pubmed: 30386108
pmcid: 6209568
Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388(17):1547–1558
doi: 10.1056/NEJMoa2214122
pubmed: 36912538
Rosenbrock J, Baues C, Kreis M, Fouassi R, Celik E, Paffenholz P et al (2023) Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer. Strahlenther Onkol 199(6):574–584
doi: 10.1007/s00066-023-02060-2
pubmed: 36930248
pmcid: 10212800
Chung SY, Koom WS, Keum KC, Chang JS, Shin SJ, Ahn JB et al (2019) Treatment outcomes of re-irradiation in Locoregionally recurrent rectal cancer and clinical significance of proper patient selection. Front Oncol 9:529
doi: 10.3389/fonc.2019.00529
pubmed: 31275858
pmcid: 6593136
Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D et al (2021) NRG oncology updated international consensus Atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol Biol Phys 109(1):174–185
doi: 10.1016/j.ijrobp.2020.08.034
pubmed: 32861817
Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V (2012) Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Radiother Oncol 104(2):181–186
doi: 10.1016/j.radonc.2012.07.003
pubmed: 22853851
Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T et al (2017) Brachytherapy for patients with prostate cancer: American society of clinical oncology/cancer care ontario joint guideline update. J Clin Oncol 35(15):1737–1743
doi: 10.1200/JCO.2016.72.0466
pubmed: 28346805
Henry A, Pieters BR, Siebert AF, Hoskin P, UgoGEwebtEAo (2022) GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol 167:244–251
doi: 10.1016/j.radonc.2021.12.047
pubmed: 34999134
Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, American Brachytherapy Society Task Group Report et al (2017) Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16(1):1–12
doi: 10.1016/j.brachy.2016.09.006
pubmed: 27771243
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer – 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262
doi: 10.1016/j.eururo.2020.09.042
pubmed: 33172724
Moll M, Nechvile E, Kirisits C, Komina O, Pajer T, Kohl B et al (2024) Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients. Strahlenther Onkol
Shen B, Liu J, Wu D, Guo J (2024) Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis. Strahlenther Onkol
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487
doi: 10.1016/S1470-2045(07)70143-2
pubmed: 17482880
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 28(7):1106–1111
doi: 10.1200/JCO.2009.25.8475
pubmed: 20124169
pmcid: 2834463
Wu SY, Wong AC, Shinohara K, Roach M 3rd, Cunha JAM, Valdes G et al (2021) Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation. Pract Radiat Oncol 11(6):515–526
doi: 10.1016/j.prro.2021.04.007
pubmed: 34077809
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ et al (2021) A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 80(3):280–292
doi: 10.1016/j.eururo.2020.11.010
pubmed: 33309278
Drobner J, Kaldany A, Shah MS, Ghodoussipour S (2023) The Role of Salvage Radical Prostatectomy in Patients with Radiation-Resistant Prostate Cancer. Cancers (basel) 15(14)
Bittner NH, Orio PF 3rd, Merrick GS, Prestidge BR, Hartford AC, Rosenthal SA (2017) The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy 16(1):59–67
doi: 10.1016/j.brachy.2016.06.003
pubmed: 28109632
Bittner NHJ, Cox BW, Davis B, King M, Lawton CAF, Merrick GS et al (2022) ACR-ABS-ASTRO practice parameter for transperineal permanent brachytherapy of prostate cancer. Am J Clin Oncol 45(6):249–257
doi: 10.1097/COC.0000000000000915
pubmed: 35588224
Collettini F, Schreiber N, Schnapauff D, Denecke T, Wust P, Schott E et al (2015) CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 191(5):405–412
doi: 10.1007/s00066-014-0781-3
pubmed: 25404063
Damm R, Streitparth T, Hass P, Seidensticker M, Heinze C, Powerski M et al (2019) Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial. Strahlenther Onkol 195(11):982–990
doi: 10.1007/s00066-019-01501-1
pubmed: 31346674
Koutrouvelis PG, Theodorescu D, Katz S, Lailas N, Hendricks F (2005) Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. J Urol 173(1):82–85 (discussion 5–6)
doi: 10.1097/01.ju.0000146043.65229.9b
pubmed: 15592034
Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR et al (2009) High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy 8(4):339–344
doi: 10.1016/j.brachy.2009.02.004
pubmed: 19428310
Celentano G, Creta M, Napolitano L, Abate M, La Rocca R, Capece M et al (2022) Prostate cancer diagnosis, treatment and outcomes in patients with previous or synchronous colorectal cancer: a systematic review of published evidence. Diagnostics (Basel) 12(6)